# Colony Stimulating Factors

## Length of Authorizations

Approval based upon diagnosis below:

| Diagnosis | Approval Length |
| --------- | ----------------|
| Acute Myeloid Leukemia (AML) | 14 days or duration of chemotherapy regimen |
| Malignancy at risk for febrile neutropenia or undergoing myeloablative chemotherapy prior to allogeneic or autologous bone marrow transplantation          | 14 days or duration of chemotherapy regimen |
| Myeloid Engraftment for bone marrow transplant (BMT)   | 30 days     |
| Severe, chronic neutropenia with absolute neutrophil count (ANC) of less than 500/mm3 and have symptoms associated with neutropenia (e.g. fever, infections, oropharyngeal ulcers). | 30 days              |
| Hematopoietic radiation injury syndrome       | 30 days              |

**All Authorizations**

Must be prescribed in accordance with FDA approved labeling

## Additional Criteria

### Non-Preferred

-   Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) **OR**
    -   For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation
-   Must have had an inadequate clinical response of at least **14 days** with at least **one preferred** drug
    -   For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)
    -   For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)

### Subsequent Authorization

-   Must provide documentation of patientâ€™s clinical response to treatment and ongoing safety monitoring

## Formulary

Blood Formation, Coagulation, and Thrombosis Agents: Colony Stimulating Factors

| PREFERRED    | NON-PREFERRED |
| ------------ | ------------- |
| Neupogen PA  | Fulphila      |
| Releuko PA   | Granix        |
| Ziextenzo PA | Leukine       |
|              | Neulasta      |
|              | Nivestym      |
|              | Nyvepria      |
|              | Udenyca       |
|              | Zarxio        |

## Links

[Criteria](https://pharmacy.medicaid.ohio.gov/sites/default/files/20220415_UPDL_Criteria_FINAL_.pdf#page=10)

[Preferred Drug List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20220701_UPDL_FINAL.pdf#page=7)
